Japan's Shionogi Patent Data At Center Of U.S. Dispute Over Crestor
This article was originally published in PharmAsia News
Alleged omissions by Japan's Shionogi when it submitted patent information lies at the heart of a major U.S. patent dispute over the blockbuster cholesterol drug Crestor (rosuvastatin)
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.